Heteromultivalent topology-matched nanostructures as potent and broad-spectrum influenza A virus inhibitors

Sci Adv. 2021 Jan 1;7(1):eabd3803. doi: 10.1126/sciadv.abd3803. Print 2021 Jan.

Abstract

Here, we report the topology-matched design of heteromultivalent nanostructures as potent and broad-spectrum virus entry inhibitors based on the host cell membrane. Initially, we investigate the virus binding dynamics to validate the better binding performance of the heteromultivalent moieties as compared to homomultivalent ones. The heteromultivalent binding moieties are transferred to nanostructures with a bowl-like shape matching the viral spherical surface. Unlike the conventional homomultivalent inhibitors, the heteromultivalent ones exhibit a half maximal inhibitory concentration of 32.4 ± 13.7 μg/ml due to the synergistic multivalent effects and the topology-matched shape. At a dose without causing cellular toxicity, >99.99% reduction of virus propagation has been achieved. Since multiple binding sites have also been identified on the S protein of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), we envision that the use of heteromultivalent nanostructures may also be applied to develop a potent inhibitor to prevent coronavirus infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology
  • Binding Sites
  • Cell Membrane / metabolism
  • Dogs
  • Erythrocyte Membrane / virology
  • Hemagglutinin Glycoproteins, Influenza Virus / chemistry*
  • Humans
  • Influenza A virus / drug effects*
  • Influenza A virus / physiology
  • Influenza, Human / virology*
  • Madin Darby Canine Kidney Cells
  • Nanoparticles / chemistry*
  • Neuraminidase / chemistry*
  • Protein Binding
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus
  • Virion
  • Virus Attachment / drug effects
  • Virus Internalization / drug effects

Substances

  • Antiviral Agents
  • H1N1 virus hemagglutinin
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • Neuraminidase